NASDAQ$VERA
Vera Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Vera Therapeutics reported its business highlights and financial results.
Vera Therapeutics reported a net loss of $16.8 million for the fourth quarter of 2021, with $79.7 million in cash and cash equivalents as of December 31, 2021. The company highlighted the progress of its clinical trials for atacicept and MAU868, and the strengthening of its balance sheet through an equity offering.
- Phase 2b ORIGIN clinical trial of atacicept is on track, with topline data expected in Q4 2022.
- MAU868 was acquired, a first-in-class monoclonal antibody to treat BK Virus infections, with full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022.
- Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis is planned for 2H-2022.
- The balance sheet was strengthened by completing an equity offering with net proceeds of approximately $80.2 million in February 2022.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$362K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro